A ‘Skin Spray’ could cure Chronic Skin Wounds caused by Diabetes

02/06/2016 - 2 minutes

Avita has initiated a trial in the UK to evaluate the potential of its ReGenerCell technology to treat diabetic foot ulcers, a skin wound that can be very hard to treat. 

avita_medical_autologous_skin_sprayWith offices in the UK and originally from Australia, Avita Medical is developing products in tissue engineering and regenerative medicine.

Its technology utilises the patient’s own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects.

The ReGenerCell device enables medical professionals to use a small sample of the patient’s skin to create an autologous suspension, containing multiple types of cells and wound-healing factors.

This suspension is then sprayed or dripped in the wound’s area.

Now, Avita is tackling a new condition, diabetic foot ulcer. It has enrolled the first patient at the Manchester Royal Infirmary for a 26-week trial. The study will have up to 24 patients, all still undergoing standard treatments – 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member